Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:CLLS NASDAQ:FMTX NASDAQ:INBX NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$9.33-1.6%$7.91$5.01▼$18.71$55.62M0.18117,227 shs13,869 shsCLLSCellectis$1.63-1.5%$1.49$1.10▼$2.43$90.32M2.91216,647 shs3,465 shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsINBXInhibrx Biosciences$22.09+5.3%$14.08$10.80▼$22.10$317.91M-0.0497,418 shs14,670 shsKRYSKrystal Biotech$148.27-1.0%$136.18$122.80▼$219.34$4.29B0.67287,318 shs120,938 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+2.71%+18.35%+3.95%+71.43%+5.10%CLLSCellectis+1.54%+4.10%+17.02%+14.58%-15.38%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%INBXInhibrx Biosciences+0.29%+28.83%+36.50%+80.71%+61.76%KRYSKrystal Biotech+0.56%+4.71%+8.34%-9.25%-22.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics4.1273 of 5 stars3.33.00.04.70.62.50.6CLLSCellectis3.1437 of 5 stars3.53.00.00.02.62.50.6FMTXForma TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AINBXInhibrx Biosciences1.8776 of 5 stars0.01.00.04.61.92.51.3KRYSKrystal Biotech4.5857 of 5 stars3.51.00.04.72.92.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.57Moderate Buy$17.7590.25% UpsideCLLSCellectis 3.00Buy$4.00146.15% UpsideFMTXForma Therapeutics 0.00N/AN/AN/AINBXInhibrx Biosciences 2.00HoldN/AN/AKRYSKrystal Biotech 3.00Buy$213.7544.17% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, KRYS, FMTX, CLLS, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$155.00 ➝ $176.006/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.005/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/15/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.005/7/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.00 ➝ $219.005/6/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.00 ➝ $240.004/28/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$221.00 ➝ $240.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$199.73M0.28N/AN/A($16.89) per share-0.55CLLSCellectis$49.22M1.83N/AN/A$2.36 per share0.69FMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90INBXInhibrx Biosciences$200K1,599.46$122.73 per share0.18$9.23 per share2.39KRYSKrystal Biotech$290.52M14.75$4.62 per share32.11$32.90 per share4.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)CLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)FMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/AINBXInhibrx Biosciences$1.69B$116.750.19N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1635.6614.71N/A37.17%14.64%13.28%8/4/2025 (Estimated)Latest ATRA, KRYS, FMTX, CLLS, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025N/ACLLSCellectis-$0.15N/AN/AN/A$10.07 millionN/A8/4/2025Q2 2025KRYSKrystal Biotech$1.20N/AN/AN/A$95.42 millionN/A5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/A5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AFMTXForma TherapeuticsN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.570.57CLLSCellectis0.441.671.67FMTXForma TherapeuticsN/A12.7412.74INBXInhibrx Biosciences1.045.125.12KRYSKrystal BiotechN/A9.659.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%CLLSCellectis63.90%FMTXForma Therapeutics87.39%INBXInhibrx Biosciences82.46%KRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.00%CLLSCellectis16.41%FMTXForma Therapeutics5.79%INBXInhibrx Biosciences17.09%KRYSKrystal Biotech13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3305.96 million5.72 millionOptionableCLLSCellectis29055.58 million46.46 millionOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionableINBXInhibrx Biosciences16614.48 million12.00 millionOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableATRA, KRYS, FMTX, CLLS, and INBX HeadlinesRecent News About These CompaniesCiti raises Krystal Biotech stock price target to $176 on KB801 trial ...July 11 at 6:11 AM | investing.comQ2 EPS Estimates for Krystal Biotech Decreased by AnalystJuly 11 at 5:48 AM | marketbeat.comKRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock UpJuly 10 at 1:11 PM | zacks.comPrincipal Financial Group Inc. Has $22.78 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)July 10 at 4:15 AM | marketbeat.comPittsburgh tech's future isn't guaranteed, CEO warnsJuly 9 at 7:12 PM | msn.comKrystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic KeratitisJuly 9 at 7:00 AM | globenewswire.comAllspring Global Investments Holdings LLC Decreases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)July 9 at 3:32 AM | marketbeat.comHigh Insider Ownership In 3 Promising Growth CompaniesJuly 8 at 1:39 PM | finance.yahoo.comAnalysts Offer Predictions for Krystal Biotech Q2 EarningsJuly 4, 2025 | americanbankingnews.comKrystal Biotech Inc. Research & Ratings | KRYS - Barron'sJuly 3, 2025 | barrons.comFY2026 EPS Estimates for Krystal Biotech Reduced by AnalystJuly 3, 2025 | americanbankingnews.comKrystal Biotech, Inc.'s (NASDAQ:KRYS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?July 3, 2025 | finance.yahoo.comClear Street Initiates Coverage of Krystal Biotech (KRYS) with Buy RecommendationJuly 3, 2025 | msn.comPeering Into Krystal Biotech's Recent Short InterestJuly 3, 2025 | benzinga.comKrystal Biotech Q2 EPS Estimate Lowered by HC WainwrightJuly 2, 2025 | marketbeat.comDino A Rossi Exhibits Confidence With An Acquisition Of Krystal Biotech Stock Options Worth $6KJuly 1, 2025 | benzinga.comInsider Decision Unfolding At Krystal Biotech: Christopher Mason Exercises Options, Resulting In $0July 1, 2025 | benzinga.comHC Wainwright Reduces Earnings Estimates for Krystal BiotechJuly 1, 2025 | marketbeat.comLisanti Capital Growth LLC Acquires Shares of 30,410 Krystal Biotech, Inc. (NASDAQ:KRYS)June 29, 2025 | marketbeat.comStrength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? - NasdaqJune 27, 2025 | nasdaq.com3 Promising Genomics Stocks to Keep an Eye On in 2025June 27, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRA, KRYS, FMTX, CLLS, and INBX Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$9.33 -0.15 (-1.58%) As of 01:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Cellectis NASDAQ:CLLS$1.62 -0.03 (-1.52%) As of 01:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Forma Therapeutics NASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Inhibrx Biosciences NASDAQ:INBX$22.09 +1.11 (+5.30%) As of 02:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Krystal Biotech NASDAQ:KRYS$148.27 -1.47 (-0.98%) As of 02:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
